A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1407-1416

  Schwartz, Laurent ^a   Abolhassani, Mohammad ^b   Guais, Adeline ^c   Sanders, Edward ^c   Steyaert, Jean Marc ^d   Campion, Frederic ^c   Israël, Maurice ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c Biorebus   (France)

^d ECOLE POLYTECHNIQUE   (France)

^e NONE   (France)

Author keywords

ATP citrate lyase; Metabolic therapy; Pyruvate dehydrogenase

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE LYASE; ANTINEOPLASTIC AGENT; CALCIUM HYDROXYCITRIC ACID; CISPLATIN; FLUOROURACIL; PYRUVATE DEHYDROGENASE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CARCINOMA; MELANOMA; MELANOMA B16; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP CITRATE (PRO-S)-LYASE; CARCINOMA, LEWIS LUNG; CELL DEATH; CELL PROLIFERATION; CISPLATIN; CITRATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; ENZYME INHIBITORS; FLUOROURACIL; HT29 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PYRUVATE DEHYDROGENASE (LIPOAMIDE); THIOCTIC ACID; TIME FACTORS; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 77950841021     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000778     Document Type: Article

References (70)

1. Warburg O: On The origin of cancer cells. Science 123: 309-314, 1956.
2. Vander Heiden MG, Cantley LC and Thompson CG: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
3. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
4. Gillies RJ and Gatenby RA: Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 39: 251-257, 2007.
5. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE and Phelphs ME: A tabulated summary of the FDG PET literature. J Nucl Med 42: S1-S93, 2001.
6. Robey RB and Hay N: Is Akt the 'Warburg kinase'? Semin Cancer Biol 10: 25-31, 2009.
7. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A and Saavedra E: Energy metabolism in tumor cells. FEBS J 274: 1393-1418, 2007.
8. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004.
9. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MR, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899, 2004.
10. Kim J, Gao P, Liu YC, Semenza GL and Dang CV: Hypoxia inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27: 7381-7393, 2007.
11. Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M and Alberghina L: Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 25: 5391-5404, 2006.
12. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
13. Schwartz L, Balosso J, Baillet F, Brun B, Amman JP and Sasco AJ: Cancer: the role of extracellular disease. Med Hypotheses 58: 340-346, 2002.
14. Abolhassani M, Wertz X, Pooya M, Chaumet-Riffaud P, Guais A and Schwartz L: Hyperosmolarity causes inflammation through the methylation of protein phosphatase 2A. Inflamm Res 57: 419-429, 2008.
15. Schwartz L, Abolhassani M, Pooya M, Steyaert J-M, Wertz X, Israël M, Guais A and Chaumet-Riffaud P: Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A. Am J Physiol Gastrointest Liver Physiol 295: G934-G941, 2008.
16. Schwartz L, Guais A, Pooya M and Abolhassani M: Is inflammation a consequence of extracellular hyperosmolarity? J Inflamm 6: 21, 2009.
17. Abolhassani M, Guais A, Chaumet-Riffaud P, Sasco AJ and Schwartz L: Carbon dioxide inhalation causes pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol 296: L657-L665, 2009.
18. Pederson PL: Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancer's most common phenotypes, the 'Warburg effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211-222, 2007.
19. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
20. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC and Harris AL: Tumor and Angiogenesis Research Group: Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non-small cell lung cancer and tumor-associated stroma. Neoplasia 7: 1-6, 2005.
21. Lu H, Forbes RA and Verma A: Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277: 23111-23115, 2005.
22. Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA and Thompson CB: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311-321, 2005.
23. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B and Michelakis ED: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37-51, 2007.
24. Michelakis ED, Webster L and Mackey JR: Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99: 989-994, 2008.
25. Koukourakis MI, Giatromanolaki A, Bougioukas G and Sivridis E: Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 6: 1476-1479, 2007.
26. Korotchkina LG, Sidhu S and Patel MS: R-Lipoic acid inhibits mammalian pyruvate dehydrogenase kinase. Free Radic Res 38: 1083-1092, 2004.
27. Szutowicz A, Kwiatkowski J and Angielski S: Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer 39: 681-687, 1979.
28. Turyn J, Schlichtholz B, Dettlaff-Pokora A, Presler M, Goyke E, Matuszewski M, Kmiec Z, Krajka K and Swierczynski J: Increased, activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer. Horm Metab Res 35: 565-569, 2003.
29. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K and Ishikawa Y: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 68: 8547-8554, 2008.
30. Berkhout TA, Havekes LM, Pearce NG and Groot PHE: The effect of (-)-hydroxycitrate on the activity of the low-densitylipoportein receptor and 3-hydroxy-3-methylglutaryl.CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J 272: 181-186, 1990.
31. Senner A and Malaisse WJ: Hexose metabolism in pancreatic islets. Effect of (-)-hydroxycitrate upon fatty acid synthesis and insulin release in glucose-stimulated islets. Biochimie 73: 1287-1290, 1991.
32. Lim K, Ryu S, Suh H, Ishihara K and Fushiki T: (-)-Hydroxycitrate ingestion and endurance exercise performance. J Nutr Sci Vitaminol 51: 1-7, 2005.
33. Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, Pharmacology and Toxicology, July 2005.
34. Ikemoto S, Sugimura K, Wada S, Yasumoto K, Yamamoto K and Kishimoto T: Augmentation of antitumor activity of 5'-deoxy- 5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo. Cancer Lett 145: 121-126, 1999.
35. Nishikawa T, Kohjimoto Y, Nishihata M, Ebisuno S and Hara I: Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines. Urology 74: 1370-1376, 2009.
36. Ghosh S and Maity P: Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Int Immunopharmacol 7: 1598-1608, 2007.
37. Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, Wen YJ, Xiao F, Yao B, Zhang R, Peng F, Jiang Y, Luo F, Zhao X, Zhang L, Zhou Q and Wei YQ: Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 11: 4217-4224, 2005.
38. Bissery MC and Chabot GG: History and new development of screening and evaluation methods of anticancer drugs used in vivo and in vitro. Bull Cancer 78: 587-602, 1991.
39. Faul F, Erdfelder E, Lang AG and Buchner A: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191, 2007.
40. Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707, 2008.
41. Young CD and Anderson SM: Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 10: 202, 2008.
42. Dang CF, Kim J, Gao P and Yustein J: The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51-56, 2008.
43. Liu H, Schwartz MJ, Hwang DH and Scherr DS: Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma. BJU Int 101: 894-901, 2008.
44. Culp WD, Neal R, Massey R, Egevad L, Pisa P and Garland D: Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res 5: 1332-1343, 2006.
45. Penso J and Beitner R: Clotrimazole decreases glycolysis and the viability of lung carcinoma and colon adenocarcinoma cells. Eur J Pharmacol 451: 227-235, 2002.
46. Penso J and Beitner R: Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology. Mol Genet Metab 76: 181-188, 2002.
47. Tuganova A, Klyuaeva A and Popov K: Recognition of the inner lipoyl-bearing domain of dihydrolipyl transacetylase and of the blood glucose-lowering compound AZD7545 by pyruvate dehydrogenase kinase 2. Biochemistry 46: 8592-8602, 2007.
48. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B and Gillies RJ: Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66: 5216-5223, 2006.
49. Israel M and Schwartz L: Cancer as a Dysmethylation Syndrome. John Libbey, Paris, 2006.
50. McFate T, Mohyelden A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, Harris RA and Verma A: Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in human cancer cells. J Biol Chem 283: 22700-22708, 2008.
51. Van de Mark K, Chen JS, Steliou K, Perrine SP and Faller DV: Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol 194: 325-340, 2003.
52. Wenzel U, Nickel A and Daniel H: alpha-lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation. Apoptosis 10: 359-368, 2005. (Pubitemid 40603489)
53. Moungjaroen J, Nimmannit U, Callery PS, Wang L, Azad N, Lipipun V, Chanvorachote P and Rojanasakul Y: Reactive oxygen species mediate caspace activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down regulation. J Pharmacol Exp Ther 319: 1062-1069, 2006.
54. Simbula G, Columbano A, Ledda-Columbano GM, Sanna L, Deidda M, Diana A and Pibiri M: Increased ROS generation and p53 activation in ·-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis 12: 113-123, 2007.
55. Shi DY, Liu HL, Stern JS, Yu PZ and Liu SL: Alpha-lipoic acid induces apoptosis in hepatoma cells via the PTEN/Akt pathway. FEBS Lett 582: 1667-1671, 2008.
56. Selvakumar E and Hsieh T: Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by lipoic acid: role in cancer prevention and thereapy. J Hematol Oncol 1: 4, 2008.
57. Board M and Newsholme E: Hydroxycitrate causes altered pyruvate metabolism by tumorigenic cells. Biochem Mol Biol Int 40: 1047-1056, 1996.
58. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR and Thompson CB: ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080, 2009.
59. Cremer DR, Rabeler R, Roberts A and Lynch B. Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol 46: 29-41, 2006.
60. Soni MG, Burdock GA, Preuss HG, Stohs SJ, Ohia SE and Bagchi D: Safety assessment of (-)-hydroxycitric acid and Super CitriMax, a novel calcium/potassium salt. Food Chem Toxicol 42: 1513-1529, 2004.
61. DeVita VT, Hellman TS and Rosenberg SA: Cancer: Principles & Practice of Oncology. 8th edition, Lippincott Williams & Wilkins, Philadelphia, 2008.
62. Ruessmann HJ: German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch tätiger Arzte e.V.): Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Complications 23: 174-177, 2009.
63. Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, Dessì M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P and Floris C : Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 24: 305-313, 2008.
64. Novotny L, Rauko P and Cojocel C: Alpha-lipoic acid: the potential for use in cancer therapy. Neoplasma 55: 81-86, 2008.
65. Berkson BM, Rubin DM and Berkson AJ: The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther 5: 83-89, 2006.
66. Shay KP, Moreau RF, Smith EJ, Smith AR and Hagen TM: Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790: 1149-1160, 2009.
67. Kovacs EM and Westerterp-Plantenga MS: Effects of (-)-hydroxycitrate on net fat synthesis as de novo lipogenesis. Physiol Behav 88: 371-381, 2006.
68. Downs BW, Bagchi M, Subbaraju GV, Shara MA, Preuss HG and Bagchi D: Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. Mutat Res 579: 149-162, 2005. (Pubitemid 41540139)
69. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P and Brugge JS: Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113, 2009.
70. Gottlieb E: Cancer: The fat and the furious. Nature 461: 44-45, 2009.